

# Jonas Mattsson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3431413/publications.pdf>

Version: 2024-02-01

219  
papers

4,736  
citations

94433

37  
h-index

138484

58  
g-index

219  
all docs

219  
docs citations

219  
times ranked

5272  
citing authors

#	ARTICLE	IF	CITATIONS
1	Graft Failure after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 165-170.	2.0	162
2	Dose Study of Thymoglobulin During Conditioning for Unrelated Donor Allogeneic Stem-Cell Transplantation. <i>Transplantation</i> , 2004, 78, 122-127.	1.0	153
3	Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 346-352.	3.5	153
4	RESULTS OF DIFFERENT STRATEGIES FOR REDUCING CYTOMEGALOVIRUS-ASSOCIATED MORTALITY IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS <sup>1</sup> . <i>Transplantation</i> , 1998, 66, 1330-1334.	1.0	150
5	Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center Study. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1688-1697.	2.0	131
6	Rapid Salvage Treatment With Virus-Specific T Cells for Therapy-Resistant Disease. <i>Clinical Infectious Diseases</i> , 2012, 55, 1064-1073.	5.8	116
7	Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. <i>Transplantation</i> , 2004, 78, 122-7.	1.0	109
8	Effect of Total Nucleated and CD34+ Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 889-893.	2.0	106
9	Prenatal T-cell reconstitution after in utero transplantation with fetal liver cells in a patient with X-linked severe combined immunodeficiency. <i>American Journal of Obstetrics and Gynecology</i> , 2002, 187, 475-482.	1.3	93
10	Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 674-682.	2.0	88
11	T CELL MIXED CHIMERISM IS SIGNIFICANTLY CORRELATED TO A DECREASED RISK OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION 1. <i>Transplantation</i> , 2001, 71, 433-439.	1.0	88
12	The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. <i>Blood</i> , 2001, 98, 1982-1985.	1.4	87
13	Fetal Membrane Cells for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. <i>Stem Cells</i> , 2013, 31, 592-601.	3.2	84
14	Respiratory Syncytial Virus Infection in Recipients of Allogeneic Stem-Cell Transplantation: A Retrospective Study of the Incidence, Clinical Features, and Outcome. <i>Transplantation</i> , 2009, 88, 1222-1226.	1.0	83
15	Transplanted Bone Marrow-Derived Cells Contribute to Human Adipogenesis. <i>Cell Metabolism</i> , 2015, 22, 408-417.	16.2	75
16	A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 473-477.	4.2	74
17	Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2012, 89, 220-227.	2.2	69
18	Major ABO Blood Group Mismatch Increases the Risk for Graft Failure after Unrelated Donor Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 675-682.	2.0	68

#	ARTICLE	IF	CITATIONS
19	A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2016, 101, 1417-1425.	3.5	61
20	A Comparison of Nonmyeloablative and Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation. <i>Transplantation</i> , 2004, 78, 1014-1020.	1.0	59
21	Allogeneic Hematopoietic Stem Cell Transplantation for Inherited Disorders: Experience in a Single Center. <i>Transplantation</i> , 2006, 81, 718-725.	1.0	59
22	Hemorrhagic cystitis: a retrospective single-center survey. <i>Clinical Transplantation</i> , 2007, 21, 659-667.	1.6	59
23	Improved Survival with Ursodeoxycholic Acid Prophylaxis in Allogeneic Stem Cell Transplantation: Long-Term Follow-Up of a Randomized Study. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 135-138.	2.0	58
24	Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2001, 115, 935-944.	2.5	55
25	Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 195-203.	2.0	53
26	Unrelated Versus Related Allogeneic Stem Cell Transplantation After Reduced Intensity Conditioning. <i>Transplantation</i> , 2006, 82, 913-919.	1.0	50
27	A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning <scp>HSCT</scp> with unrelated donors. <i>Clinical Transplantation</i> , 2013, 27, E368-74.	1.6	50
28	Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1777-1784.	2.0	50
29	Serum levels of cytokines correlate to donor chimerism and acute graft-vs.-host disease after haematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2003, 70, 384-391.	2.2	47
30	Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. <i>Blood</i> , 2003, 101, 469-472.	1.4	47
31	Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 720-727.	2.0	47
32	Mesothelin-Specific CAR T Cells Target Ovarian Cancer. <i>Cancer Research</i> , 2021, 81, 3022-3035.	0.9	45
33	The TNFd4 allele is correlated to moderate-to-severe acute graft-versus-host disease after allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2002, 119, 1133-1136.	2.5	43
34	Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2003, 122, 788-794.	2.5	42
35	Metabolic regulation of CAR T cell function by the hypoxic microenvironment in solid tumors. <i>Immunotherapy</i> , 2019, 11, 335-345.	2.0	42
36	Analysis of Donor and Recipient ABO Incompatibility and Antibody-Associated Complications after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 264-271.	2.0	41

#	ARTICLE	IF	CITATIONS
37	Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy. <i>Haematologica</i> , 2015, 100, 1477-1485.	3.5	41
38	Increased gene expression of chemokine receptors is correlated with acute graft-versus-host disease after allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 280-287.	2.0	37
39	Case-Control Comparison of At-Home and Hospital Care for Allogeneic Hematopoietic Stem-Cell Transplantation: The Role of Oral Nutrition. <i>Transplantation</i> , 2008, 85, 1000-1007.	1.0	37
40	Second allogeneic hematopoietic stem cell transplantation: a treatment for graft failure. <i>Clinical Transplantation</i> , 2011, 25, E68-E76.	1.6	37
41	Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease. <i>Frontiers in Immunology</i> , 2017, 8, 717.	4.8	37
42	Thymic function after allogeneic stem cell transplantation is dependent on graft source and predictive of long term survival. <i>Clinical Immunology</i> , 2012, 142, 343-350.	3.2	35
43	Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD. <i>Bone Marrow Transplantation</i> , 2020, 55, 1773-1783.	2.4	35
44	Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes. <i>Oncotarget</i> , 2016, 7, 23581-23593.	1.8	35
45	Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment. <i>Seminars in Cancer Biology</i> , 2022, 86, 207-223.	9.6	35
46	Decreased Serum Levels of Clara Cell Secretory Protein (CC16) Are Associated with Bronchiolitis Obliterans and May Permit Early Diagnosis in Patients after Allogeneic Stem-Cell Transplantation. <i>Transplantation</i> , 2005, 79, 1411-1416.	1.0	34
47	Chimerism Patterns of Long-Term Stable Mixed Chimeras Posthematopoietic Stem Cell Transplantation in Patients with Nonmalignant Diseases: Follow-Up of Long-Term Stable Mixed Chimerism Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 838-844.	2.0	34
48	Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination. <i>Oncolmunology</i> , 2020, 9, 1792058.	4.6	30
49	TRANSPLANTATION OF AUTOLOGOUS AND ALLOGENEIC BONE MARROW WITH LIVER FROM A CADAVERIC DONOR FOR PRIMARY LIVER CANCER1. <i>Transplantation</i> , 2000, 69, 2043-2048.	1.0	30
50	Granulocyte Colony-Stimulating Factor Induced Acute and Chronic Graft-Versus-Host Disease. <i>Transplantation</i> , 2010, 90, 1022-1029.	1.0	29
51	Clinical Expansion of Cord Blood-derived T Cells for Use as Donor Lymphocyte Infusion After Cord Blood Transplantation. <i>Journal of Immunotherapy</i> , 2010, 33, 96-105.	2.4	29
52	Varicella-Zoster Reactivation after Allogeneic Stem Cell Transplantation without Routine Prophylaxis—The Incidence Remains High. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1646-1649.	2.0	29
53	Decreasing mortality rate in early pneumonia following hematopoietic stem cell transplantation. <i>Scandinavian Journal of Infectious Diseases</i> , 2006, 38, 970-976.	1.5	28
54	Facing the future: challenges and opportunities in adoptive T cell therapy in cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 811-827.	3.1	27

#	ARTICLE	IF	CITATIONS
55	Mesenchymal Stem Cells Inhibit Thymic Reconstitution After Allogeneic Cord Blood Transplantation. <i>Stem Cells and Development</i> , 2012, 21, 1409-1417.	2.1	26
56	Improved overall survival for pediatric patients undergoing allogeneic hematopoietic stem cell transplantation â€“ A comparison of the last two decades. <i>Pediatric Transplantation</i> , 2016, 20, 667-674.	1.0	26
57	Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 60-69.	2.4	26
58	Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1728-1737.	2.0	25
59	Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders. <i>European Journal of Haematology</i> , 2011, 87, 503-509.	2.2	24
60	Effects of different serum-levels of ATG after unrelated donor umbilical cord blood transplantation. <i>Transplant Immunology</i> , 2012, 27, 59-62.	1.2	24
61	Multicenter evaluation of parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 2198-2205.	4.7	24
62	Quality of the hematopoietic stem cell graft affects the clinical outcome of allogeneic stem cell transplantation. <i>Transfusion</i> , 2015, 55, 2339-2350.	1.6	23
63	Long-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant?. <i>PLoS ONE</i> , 2016, 11, e0154737.	2.5	23
64	Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely option. <i>American Journal of Hematology</i> , 2021, 96, 179-187.	4.1	23
65	Identification of Maternal Hematopoietic Cells in a 2nd-Trimester Fetus. <i>Fetal Diagnosis and Therapy</i> , 2005, 20, 355-358.	1.4	22
66	Immune modulation to prevent antibody-mediated rejection after allogeneic hematopoietic stem cell transplantation. <i>Transplant Immunology</i> , 2011, 25, 153-158.	1.2	22
67	Update on viral infections in lung transplantation. <i>Current Opinion in Pulmonary Medicine</i> , 2012, 18, 264-270.	2.6	22
68	Many Days at Home during Neutropenia after Allogeneic Hematopoietic Stem Cell Transplantation Correlates with Low Incidence of Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 314-320.	2.0	22
69	Effect of Graft-versus-Host Disease Prophylaxis Regimens on T and B Cell Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1260-1268.	2.0	21
70	Factors With an Impact on Chimerism Development and Long-Term Survival After Umbilical Cord Blood Transplantation. <i>Transplantation</i> , 2012, 94, 1066-1074.	1.0	20
71	Hospital care or home care after allogeneic hematopoietic stem cell transplantation â€“ Patients' experiences of care and support. <i>European Journal of Oncology Nursing</i> , 2013, 17, 389-395.	2.1	20
72	Allogenic stem cell transplantation for nonmalignant disorders using matched unrelated donors. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 877-882.	2.0	19

#	ARTICLE	IF	CITATIONS
73	Novel Antibodies to the Donor Stem Cell Population CD34+VEGFR-2+ Are Associated With Rejection After Hematopoietic Stem Cell Transplantation. <i>Transplantation</i> , 2008, 86, 686-696.	1.0	19
74	Posaconazole Concentrations in Human Tissues after Allogeneic Stem Cell Transplantation. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4941-4943.	3.2	19
75	The Metabolic Profile of Tumor and Virally Infected Cells Shapes Their Microenvironment Counteracting T Cell Immunity. <i>Frontiers in Immunology</i> , 2019, 10, 2309.	4.8	19
76	Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2019, 103, 510-518.	2.2	19
77	Polyclonal anti-T-cell globulin as part of the preparative regimen for pediatric allogeneic stem-cell transplantation. <i>Pediatric Transplantation</i> , 2001, 5, 285-292.	1.0	18
78	Liver transplantation followed by adjuvant nonmyeloablative hemopoietic stem cell transplantation for advanced primary liver cancer in humans. <i>Transplantation</i> , 2003, 75, 1061-1066.	1.0	18
79	A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease. <i>Expert Review of Hematology</i> , 2019, 12, 311-323.	2.2	18
80	Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-transplantation Cyclophosphamide and Anti-thymocyte Globulin as Graft-versus-Host Disease Prophylaxis. <i>Clinical Hematology International</i> , 2019, 1, 105-113.	1.7	18
81	Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress. , 2022, 10, e004458.		18
82	An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation. <i>European Journal of Haematology</i> , 2001, 66, 50-56.	2.2	17
83	General health, symptom occurrence, and self-efficacy in adult survivors after allogeneic hematopoietic stem cell transplantation: a cross-sectional comparison between hospital care and home care. <i>Supportive Care in Cancer</i> , 2015, 23, 1273-1283.	2.2	17
84	T-cell frequencies of CD8+ $\gamma\delta$ and CD27+ $\gamma\delta$ cells in the stem cell graft predict the outcome after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1562-1574.	2.4	17
85	Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway. <i>PLoS ONE</i> , 2017, 12, e0187294.	2.5	17
86	Molecular monitoring of T-cell chimerism early after allogeneic stem cell transplantation may predict the occurrence of acute GVHD grades II-IV. <i>Clinical Transplantation</i> , 2005, 19, 346-349.	1.6	16
87	Genomic tissue typing and optimal antithymocyte globuline dose using unrelated donors results in similar survival and relapse as HLA-identical siblings in haematopoietic stem-cell transplantation for leukaemia. <i>European Journal of Haematology</i> , 2008, 80, 419-428.	2.2	16
88	Media evaluation for production and expansion of anti-CD19 chimeric antigen receptor T cells. <i>Cytotherapy</i> , 2018, 20, 941-951.	0.7	16
89	Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant. <i>European Journal of Haematology</i> , 2021, 106, 32-39.	2.2	16
90	Improved survival after bone marrow transplantation for early leukemia using busulfan-cyclophosphamide and individualized prophylaxis against graft-versus-host disease: a long-term follow-up. <i>Clinical Transplantation</i> , 1999, 13, 512-519.	1.6	15

#	ARTICLE	IF	CITATIONS
91	Stable mixed donorâ€“donor chimerism after double cord blood transplantation. <i>International Journal of Hematology</i> , 2009, 90, 526-531.	1.6	15
92	Expanded umbilical cord blood T cells used as donor lymphocyte infusions after umbilical cord blood transplantation. <i>Cytotherapy</i> , 2014, 16, 1528-1536.	0.7	15
93	Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 1377-1387.	1.8	15
94	GVHD prophylaxis using lowâ€“dose cyclosporine improves survival in leukaemic recipients of HLAâ€“identical sibling transplants. <i>European Journal of Haematology</i> , 2010, 84, 323-331.	2.2	14
95	Long-Term Follow-Up of a Pilot Study Using Placenta-Derived Decidua Stromal Cells for Severe Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1965-1969.	2.0	14
96	C-reactive protein levels before reduced-intensity conditioning predict outcome after allogeneic stem cell transplantation. <i>International Journal of Hematology</i> , 2010, 92, 161-167.	1.6	13
97	Allogeneic Hematopoietic Cell Transplantation for GATA2 Deficiency in a Patient With Disseminated Human Papillomavirus Disease. <i>Transplantation</i> , 2014, 98, e95-e96.	1.0	13
98	Donor Cell Composition and Reactivity Predict Risk of Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Immunology Research</i> , 2016, 2016, 1-11.	2.2	13
99	Risk Factors for Severe Acute Graft-versus-Host Disease in Donor Graft Composition. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 467-477.	2.0	13
100	Donor Lymphocyte Infusion May Reduce the Incidence of Bronchiolitis Obliterans after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1214-1221.	2.0	12
101	Cord Blood T Cells Cultured With IL-7 in Addition to IL-2 Exhibit a Higher Degree of Polyfunctionality and Superior Proliferation Potential. <i>Journal of Immunotherapy</i> , 2013, 36, 432-441.	2.4	12
102	Risk Factors for Invasive Mold Infections and Implications for Choice of Prophylaxis after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1684-1689.	2.0	12
103	Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based Decisions. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 677-683.	2.0	12
104	Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections. <i>Leukemia and Lymphoma</i> , 2021, 62, 3373-3383.	1.3	12
105	Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue. <i>Oncotarget</i> , 2017, 8, 60257-60269.	1.8	12
106	Long-term outcome in patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2018, 107, 478-485.	1.6	11
107	The effect of N-acetyl-l-cysteine (NAC) on liver toxicity and clinical outcome after hematopoietic stem cell transplantation. <i>Scientific Reports</i> , 2018, 8, 8293.	3.3	11
108	Humanistic burden of patients with chronic graft-versus-host disease - systematic literature review of health-related quality of life and functional status. <i>Expert Review of Hematology</i> , 2019, 12, 295-309.	2.2	11

#	ARTICLE	IF	CITATIONS
109	Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Acta Haematologica</i> , 2021, 144, 66-73.	1.4	11
110	Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 428.e1-428.e9.	1.2	11
111	Bloodstream Infections and Outcomes Following Allogeneic Hematopoietic Cell Transplantation: A Single-Center Study. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 50.e1-50.e8.	1.2	11
112	Recent progress in allogeneic stem cell transplantation. <i>Current Opinion in Molecular Therapeutics</i> , 2008, 10, 343-9.	2.8	11
113	Novel method to characterize immune cells from human prostate tissue. <i>Prostate</i> , 2014, 74, 1391-1399.	2.3	10
114	Norovirus causing severe gastrointestinal disease following allogeneic hematopoietic stem cell transplantation: A retrospective analysis. <i>Transplant Infectious Disease</i> , 2018, 20, e12847.	1.7	10
115	Impact of central nervous system involvement in AML on outcomes after allotransplant and utility of pretransplant cerebrospinal fluid assessment. <i>European Journal of Haematology</i> , 2019, 103, 483-490.	2.2	10
116	Individualization of Hematopoietic Stem Cell Transplantation Using Alpha/Beta T-Cell Depletion. <i>Frontiers in Immunology</i> , 2019, 10, 189.	4.8	10
117	Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan+ Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical and Translational Science</i> , 2020, 13, 293-300.	3.1	10
118	Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 1908-1918.	2.4	10
119	Cyclophosphamide Alters the Gene Expression Profile in Patients Treated with High Doses Prior to Stem Cell Transplantation. <i>PLoS ONE</i> , 2014, 9, e86619.	2.5	10
120	Increased immune transcript levels are correlated with acute graft-versus-host disease and cytomegalovirus response after allogeneic stem cell transplantation. <i>Transplantation</i> , 2004, 77, 195-200.	1.0	9
121	Home care during neutropenia after allogeneic hematopoietic stem cell transplantation in children and adolescents is safe and may be more advantageous than isolation in hospital. <i>Pediatric Transplantation</i> , 2014, 18, 398-404.	1.0	9
122	Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 676-681.	2.0	9
123	Reduced-intensity conditioning allogeneic transplant with dual T-cell depletion in myelofibrosis. <i>European Journal of Haematology</i> , 2019, 103, 597-606.	2.2	9
124	High incidence but low mortality of EBV-reactivation and PTLD after alloHCT using ATG and PTCy for GVHD prophylaxis. <i>Leukemia and Lymphoma</i> , 2020, 61, 3198-3208.	1.3	9
125	Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease. <i>European Journal of Health Economics</i> , 2021, 22, 169-180.	2.8	9
126	Anti-thymocyte globulin and post-transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. <i>European Journal of Haematology</i> , 2022, 108, 61-72.	2.2	9



#	ARTICLE	IF	CITATIONS
127	Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality. <i>OncolImmunology</i> , 2022, 11, .	4.6	9
128	Systems level immune response analysis and personalized medicine. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 307-317.	3.0	8
129	T-Cell Receptor Excision Circle Levels After Allogeneic Stem Cell Transplantation Are Predictive of Relapse in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Stem Cells and Development</i> , 2014, 23, 1559-1567.	2.1	8
130	Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation. <i>International Journal of Hematology</i> , 2017, 106, 471-475.	1.6	8
131	Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPins® Proteins. <i>Journal of Immunology Research</i> , 2020, 2020, 1-12.	2.2	8
132	Clinical tolerance after allogeneic hematopoietic stem cell transplantation. <i>Transplantation</i> , 2002, 73, 930-936.	1.0	8
133	Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2020, 104, 36-45.	2.2	7
134	Placenta-Derived Decidual Stromal Cells for Graft-Versus-Host Disease, Hemorrhaging, and Toxicity after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S149.	2.0	6
135	Higher response rates in patients with severe chronic skin graft-versus-host disease treated with extracorporeal photopheresis. <i>Central-European Journal of Immunology</i> , 2019, 44, 84-91.	1.2	6
136	Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c+ Expression in Tumor. <i>Advances in Therapy</i> , 2020, 37, 5023-5031.	2.9	6
137	Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1511-1519.	2.0	6
138	Improving Safety and Outcomes After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 265.e1-265.e9.	1.2	6
139	Comparison of Algorithms for Oral Busulphan Area Under the Concentration-Time Curve Limited Sampling Estimate. <i>Clinical Drug Investigation</i> , 2014, 34, 43-52.	2.2	5
140	Reduced IL-7 Responsiveness Defined by Signal Transducer and Activator of Transcription 5 Phosphorylation in T Cells May Be a Marker for Increased Risk of Developing Cytomegalovirus Disease in Patients after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 128-132.	2.0	5
141	A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer. <i>Journal of Immunotherapy</i> , 2017, 40, 132-139.	2.4	5
142	The importance of graft cell composition in outcome after allogeneic stem cell transplantation in patients with malignant disease. <i>Clinical Transplantation</i> , 2019, 33, e13537.	1.6	5
143	Allogeneic stem cell transplant in myelodysplastic syndrome—factors impacting survival. <i>European Journal of Haematology</i> , 2020, 104, 116-124.	2.2	5
144	Outcomes of therapy-related acute lymphoblastic leukemia in adults after allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , 2020, 105, 24-29.	2.2	5

#	ARTICLE	IF	CITATIONS
145	Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy. <i>Stem Cell Reviews and Reports</i> , 2021, 17, 63-70.	3.8	5
146	Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level. <i>Annals of Hematology</i> , 2021, 100, 789-798.	1.8	5
147	Efficacy and cost analysis of eltrombopag in thrombocytopenia and poor graft function post allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2471-2476.	2.4	5
148	Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation versus Nontransplantation Therapies in Myelofibrosis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 600.e1-600.e8.	1.2	5
149	Incidence, Outcomes and Predictors of Acute Kidney Injury Post Allogeneic Stem Cell Transplant. <i>Blood</i> , 2020, 136, 16-17.	1.4	5
150	A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells <i>in vitro</i> and <i>in vivo</i>. <i>Haematologica</i> , 2022, 107, 1786-1795.	3.5	5
151	Granulocyte transfusions could benefit patients with severe oral mucositis after allogeneic hematopoietic stem cell transplantation. <i>Vox Sanguinis</i> , 2019, 114, 769-777.	1.5	4
152	Treatment of radiculomyelopathy in two patients with placenta-derived decidual stromal cells. <i>International Journal of Hematology</i> , 2020, 111, 591-594.	1.6	4
153	Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graft-versus-host disease prophylaxis. <i>Oral Diseases</i> , 2021, 27, 1217-1225.	3.0	4
154	Stable mixed double donor chimerism - Absence of war doesn't necessarily mean peace. <i>Chimerism</i> , 2010, 1, 64-65.	0.7	3
155	Expansion of T-cells from the cord blood graft as a predictive tool for complications and outcome of cord blood transplantation. <i>Clinical Immunology</i> , 2012, 143, 134-144.	3.2	3
156	The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Inherited Diseases Is Influenced by HLA Match, Year of Transplantation, and Immunized Female Donor. <i>Transplantation</i> , 2019, 103, 1247-1252.	1.0	3
157	Predictors of outcomes of therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.9	3
158	Pilot Study on Frailty and Functionality on Routine Clinical Assessment in Allogeneic Hematopoietic Cell Transplantation to Predict Outcomes. <i>Blood</i> , 2019, 134, 380-380.	1.4	3
159	Increased Frequency and Responsiveness of PSA-Specific T Cells After Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Transplantation</i> , 2009, 87, 467-472.	1.0	2
160	Major surgery in a neutropenic patient undergoing allogeneic stem cell transplantation for high risk myelofibrosis. <i>International Journal of Hematology</i> , 2012, 96, 798-800.	1.6	2
161	Epstein-Barr virus associated post-transplant lymphoproliferative disorder mimicking acute graft versus host disease. <i>European Journal of Haematology</i> , 2019, 103, 519-522.	2.2	2
162	Diagnostic disagreement between clinical standard histopathological and retrospective assessment of histopathology-based gastrointestinal graft-versus-host disease in children. <i>Pediatric Transplantation</i> , 2020, 24, e13824.	1.0	2

#	ARTICLE	IF	CITATIONS
163	Posttransplantation Lymphoproliferative Disease Treated by Replantation. Case Reports in Immunology, 2020, 2020, 1-4.	0.4	2
164	Prolactin, a potential biomarker for chronic GVHD activity. European Journal of Haematology, 2021, 106, 158-164.	2.2	2
165	Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantation. Annals of Hematology, 2021, 100, 1311-1319.	1.8	2
166	Effect of pre-transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis. European Journal of Haematology, 2021, 107, 517-528.	2.2	2
167	Allogeneic hematopoietic stem cell transplantation in patients with therapy-related hematologic malignancies developing after multiple myeloma. European Journal of Haematology, 2022, 108, 430-436.	2.2	2
168	Chronic kidney disease, survival and graft-versus-host-disease-free/relapse-free survival in recipients of allogeneic hematopoietic stem cell transplant. CKJ: Clinical Kidney Journal, 2022, 15, 1583-1592.	2.9	2
169	The 17-gene stemness score associates with relapse risk and long-term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia. EJHaem, 2022, 3, 873-884.	1.0	2
170	Relationship between certain HLA alleles and the risk of cytomegalovirus reactivation following allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease, 2022, 24, .	1.7	2
171	Chimerism and use of mesenchymal stem cells in umbilical cord blood transplantation. Chimerism, 2013, 4, 34-35.	0.7	1
172	Reply to: Transient Grades Three to Four Acute Hepatitis Is a Common Complication of Rabbit Antithymocyte Globulin (Thymoglobulin) Administered before Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1145-1146.	2.0	1
173	A Novel Method to Evaluate Outcomes of Chronic Graft Vs Host Disease by Using National Population-Based Real-World Data. Biology of Blood and Marrow Transplantation, 2019, 25, S223.	2.0	1
174	Combination of the Centre for International Blood and Marrow Transplant Registry Risk Score and the Global Severity Score Enhances Prognostic Risk Stratification in Patients Receiving Frontline Therapy for Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2019, 25, 1761-1769.	2.0	1
175	Patient-reported symptom burden of chronic graft versus host disease: a systematic literature review. Expert Review of Hematology, 2020, 13, 1119-1130.	2.2	1
176	Effect of donor age and kinship on outcomes in haplo-identical stem cell transplantation may be modulated by GVHD prophylaxis strategies. Bone Marrow Transplantation, 2021, 56, 689-691.	2.4	1
177	Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 134-140.	0.9	1
178	Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR. European Journal of Haematology, 2021, 107, 354-363.	2.2	1
179	Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes. European Journal of Haematology, 2021, 106, 508-519.	2.2	1
180	Allogeneic Stem Cell Transplantation Has Limited Benefit in Older Patients with Mixed Phenotype Acute Leukemia. Blood, 2019, 134, 5725-5725.	1.4	1

#	ARTICLE	IF	CITATIONS
181	A Novel CD34-Specific T-Cell Engager Efficiently Depletes Stem Cells and Acute Myeloid Leukemia Cells in Vitro and In Vivo. <i>Blood</i> , 2021, 138, 2861-2861.	1.4	1
182	In vitro or in vivo expansion before adoptive T-cell therapy?. <i>Immunotherapy</i> , 2011, 3, 131-133.	2.0	0
183	Risks and Benefits of Sex-Mismatched Hematopoietic Cell Transplantation Differ By Conditioning Strategy. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S340-S341.	2.0	0
184	An Increasing Severity of Chronic GvHD Is Associated to an Activated and Cytotoxic T Cell Mediated Immune-Phenotype. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S351.	2.0	0
185	Decidual Stromal Cells As Treatment for Acute Graft Versus Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S349-S350.	2.0	0
186	HLA-C Mismatch without Impact on Outcome after Allogeneic HSCT. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S160.	2.0	0
187	Long-Term Stable Mixed Chimerism in Patients Undergoing HSCT for Non-Malignant Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S182-S183.	2.0	0
188	Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S423-S424.	2.0	0
189	Placenta-Derived Decidual Stromal Cells for Treatment of Severe Acute Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S48.	2.0	0
190	Identifying Cellular Subsets Diagnostic for Severity and Organ Specific Chronic GVHD. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S415.	2.0	0
191	Community Acquired Respiratory Viral Infections (CARV) in Patients with Acute Leukemia and Hematopoietic Stem Cell Transplant (HSCT) Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S178.	2.0	0
192	No effect of HLA-C mismatch after allogeneic hematopoietic stem cell transplantation with unrelated donors and T cell depletion in patients with hematological malignancies. <i>Clinical Transplantation</i> , 2017, 31, e13012.	1.6	0
193	Long Term Follow-up of a Pilot Study Using Placenta-Derived Decidua Stromal Cells for Severe Acute Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S247.	2.0	0
194	Pre-formulation investigations for establishing a protocol for treosulfan handling and activation. <i>Pharmaceutical Development and Technology</i> , 2019, 24, 639-648.	2.4	0
195	The Effect of Donor Age on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S282.	2.0	0
196	Vitamin D levels and busulphan kinetics in patients undergoing hematopoietic stem cell transplantation, a multicenter study. <i>Bone Marrow Transplantation</i> , 2021, 56, 807-817.	2.4	0
197	Prospective Quantitative PCR Monitoring of Allogeneic Stem Cell Transplant (SCT) Patients at High Risk for EBV Associated PTLD. <i>Blood</i> , 2007, 110, 2969-2969.	1.4	0
198	Norovirus Infections in Patients with Hematological Diseases and After Stem Cell Transplantation; Epidemiological and Clinical Aspects. <i>Blood</i> , 2009, 114, 2661-2661.	1.4	0

#	ARTICLE	IF	CITATIONS
199	Improved Survival with Ursodeoxycholic Acid Prophylaxis in Allogeneic Stem Cell Transplantation: Long-Term Follow-up of a Randomized Study of the Nordic Bone Marrow Transplantation Group. Blood, 2011, 118, 488-488.	1.4	0
200	Graft Failure In Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 4559-4559.	1.4	0
201	Risks and Benefits of Sex-Mismatched Hematopoietic Cell Transplantation Differ By Conditioning Intensity. Blood, 2014, 124, 2537-2537.	1.4	0
202	Busulphan Metabolism Via Flavin-Containing Monooxygenase 3 (FMO3) Can Explain Several Interactions with Other Drugs. Blood, 2014, 124, 1150-1150.	1.4	0
203	Dual T-Cell Depletion with a Very Low Dose of ATG and Ptcy Provides an Effective Control of Acute Gvhd in PBSC RIC Allo-HSCT. Blood, 2019, 134, 5669-5669.	1.4	0
204	Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT. Blood, 2019, 134, 3344-3344.	1.4	0
205	Patient Age and Donor HLA Matching Can Stratify Allogeneic Hematopoietic Cell Transplantation (HCT) Patients into Prognostic Groups: A Collaborative Study. Blood, 2019, 134, 3341-3341.	1.4	0
206	The 17-Gene Leukemic Stemess Score Can Predict Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. Blood, 2019, 134, 3299-3299.	1.4	0
207	Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning. Blood, 2019, 134, 4590-4590.	1.4	0
208	Outcomes of Therapy Related Acute Lymphoblastic Leukemia in Adults after Allogeneic Stem Cell Transplantation - Twenty-Year Experience from a Tertiary Care Center. Blood, 2019, 134, 5717-5717.	1.4	0
209	Predictors of Outcomes in Adult Patients with Therapy Related Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - Twenty Year Experience from a Tertiary Care Centre. Blood, 2019, 134, 5737-5737.	1.4	0
210	Impact of Hematopoietic Cell Transplantation-Co-Morbidity Index (HCT-CI) and Its Individual Components on Allogeneic Transplant Outcomes. Blood, 2019, 134, 5722-5722.	1.4	0
211	No Impact of Donor's Age-Related Clonal Hematopoiesis (ARCH) Observed on Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Result from Bar-Coded Error Corrected Sequencing in 33 Gene Mutations on 372 Pairs of Donor and Recipient. Blood, 2019, 134, 4514-4514.	1.4	0
212	Improved Gvhd Free, Relapse Free Survival Using Dual T-Cell Depletion with ATG and Ptcy in Matched Unrelated Donor RIC Allo-HSCT. Blood, 2019, 134, 4594-4594.	1.4	0
213	Update of Multicenter, Retrospective Evaluation of Overall Response and Failure Free Survival Following Ruxolitinib Therapy for Heavily Pre-Treated Chronic Gvhd Patients with Steroid-Failure: A Proposal of Risk Score Model for Failure-Free Survival. Blood, 2021, 138, 3905-3905.	1.4	0
214	Single Centre, Retrospective Analysis of Extracorporeal Photopheresis (ECP) Therapy in the Patients Who Are Heavily Pre-Treated for Steroid Resistant Chronic Graft-Versus-Host Disease (GVHD). Blood, 2021, 138, 1806-1806.	1.4	0
215	Propensity Score Matching Analysis Comparing Extracorporeal Photopheresis (ECP) Vs Best Available Therapy in Third Line or Later Treatment of Chronic Graft-Versus-Host Disease (cGVHD). Blood, 2021, 138, 3896-3896.	1.4	0
216	Frailty Scale for Outcome Predictions in Hematopoietic Cell Transplanted Adults. Blood, 2021, 138, 110-110.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Outcomes of patients diagnosed with chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation: Results from a tertiary care center. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.9	0
218	Letermovir Prophylaxis for Cytomegalovirus Reactivation in Allogeneic Hematopoietic Cell Transplant Recipients: A Single Centre Experience. Transplantation and Cellular Therapy, 2022, 28, S87.	1.2	0
219	Frailty Scale for Outcome Predictions in Hematopoietic Cell Transplanted Adults. Transplantation and Cellular Therapy, 2022, 28, S439-S440.	1.2	0